Beloranib
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects
Zafgen · Phase 2 · Completed · Enrollment 160
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| 0.3 mg Beloranib | n/r | n/r | n/r | n/r |
| 0.6 mg Beloranib | n/r | n/r | n/r | n/r |
| 1.2 mg Beloranib | n/r | n/r | n/r | n/r |
| 2.4 mg Beloranib | n/r | n/r | n/r | n/r |
| 3.2 mg Beloranib | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- 0.3 mg Beloranib: endpoint not reported
- 0.6 mg Beloranib: endpoint not reported
- 1.2 mg Beloranib: endpoint not reported
- 2.4 mg Beloranib: endpoint not reported
- 3.2 mg Beloranib: endpoint not reported